Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Scorletti

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Annual Review of Nutrition|July 19, 2013
Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver diseaseE Scorletti, C D Byrne
Current Diabetes Reports|March 15, 2017
Type 2 Diabetes and Hepatocellular Carcinoma: Risk Factors and PathogenesisP Wainwright, E Scorletti, C D Byrne
Endocrine|September 7, 2011
Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatmentsE Scorletti, P C Calder, C D Byrne
Journal of Hepatology|November 28, 2017
Reply to: "Energy drinks and adolescents - A hepatic health hazard?"Valerio Nobili, A Mosca, E Scorletti, et al.
Journal of Hepatology|July 11, 2017
Reply to: "Fructose, uric acid and zonal differences in NASH"V Nobili, A Mosca, E Scorletti, et al.
Clinical and Experimental Rheumatology|February 13, 2009
Diffuse skin reaction after changing the etanercept formulationR Caporali, F Bobbio-Pallavicini, M Caprioli, et al.
Diabetes & Metabolism|January 11, 2020
Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trialsA Mantovani, C D Byrne, E Scorletti, et al.
Lupus|July 26, 2013
Chromosomally integrated human herpesvirus 6 in a patient with systemic lupus erythematosusL Cavagna, E Scorletti, F Inverardi, et al.
Contemporary Clinical Trials|February 22, 2014
Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected]E Scorletti, L Bhatia, K G McCormick, et al.
European Journal of Clinical Nutrition|August 17, 2017
Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot studyL Hodson, L Bhatia, E Scorletti, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Annual Review of Nutrition|July 19, 2013
Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver diseaseE Scorletti, C D Byrne
Current Diabetes Reports|March 15, 2017
Type 2 Diabetes and Hepatocellular Carcinoma: Risk Factors and PathogenesisP Wainwright, E Scorletti, C D Byrne
Endocrine|September 7, 2011
Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatmentsE Scorletti, P C Calder, C D Byrne
Journal of Hepatology|November 28, 2017
Reply to: "Energy drinks and adolescents - A hepatic health hazard?"Valerio Nobili, A Mosca, E Scorletti, et al.
Journal of Hepatology|July 11, 2017
Reply to: "Fructose, uric acid and zonal differences in NASH"V Nobili, A Mosca, E Scorletti, et al.
Clinical and Experimental Rheumatology|February 13, 2009
Diffuse skin reaction after changing the etanercept formulationR Caporali, F Bobbio-Pallavicini, M Caprioli, et al.
Diabetes & Metabolism|January 11, 2020
Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trialsA Mantovani, C D Byrne, E Scorletti, et al.
Lupus|July 26, 2013
Chromosomally integrated human herpesvirus 6 in a patient with systemic lupus erythematosusL Cavagna, E Scorletti, F Inverardi, et al.
Contemporary Clinical Trials|February 22, 2014
Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected]E Scorletti, L Bhatia, K G McCormick, et al.
European Journal of Clinical Nutrition|August 17, 2017
Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot studyL Hodson, L Bhatia, E Scorletti, et al.
Pageof 2